Navigation Links
delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation
Date:8/4/2009

SOUTH BURLINGTON, Vt., Aug. 4 /PRNewswire-FirstCall/ -- delSECUR CORPORATION, a Nevada Corporation, (Pink Sheets: DLSC) announced today that its Board of Directors has accepted, subject to the approval of the majority of the shareholders entitled to vote, an agreement to purchase the Intellectual Property Assets of delSECUR CORPORATION. The consideration for such purchase will be in the form of a 49% interest in the shares of common stock of Q Tech Systems, Inc., an Ontario, Canada Corporation.

The primary asset to be acquired by Q Tech is the del-ID technology, a patented device and system of authenticating individuals through biometric means invented by Pierre de Lanauze, the former President & CEO of delSECUR. Q Tech, which also develops and markets technologies to enhance security and identification processes, plans to incorporate the del-ID technology with its proprietary technology. "Q Tech will be immediately focusing on the invention of Pierre de Lanauze's analog technology and believes it can make this combined technology commercially viable and bring it to the marketplace," said Randall McCormick, delSECUR's current CEO.

Mr. McCormick further stated, "We believe this is a great opportunity for the advancement of the del-ID technology and puts our business plan and mission statement immediately into action without further delay.

It is time to bring the del-Id technology to the next level and to test its capabilities. With this new alliance we are much closer to that goal."

delSECUR, a public company (Pink Sheets: DLSC) with its head office in S. Burlington, VT., is a technology development company of a unique authentication process based on abstract images of biological data collected from the fingers of living persons.

For further information contact us at:

SOURCE delSECUR CORPORATION
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. delSECUR CORPORATION Announces Appointment of the Companys President & CEO
2. $29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation
3. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
4. Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results
5. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
6. Carbon Disclosure Project: Worlds largest corporations seek clarity on climate change regulation
7. L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation
8. Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results
9. Corporations can profit from being environmentally friendly
10. Communication Intelligence Corporation Closes $3.6 Million Financing
11. MXI Security and Communication Intelligence Corporation Team up to Deliver the First Green Portable Security Solution for Financial Institutions

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...AFAYETTE, Ind. - Purdue University scientists have... responsible for cell wall development in maize, a...ys to produce the biomass best suited for biofuels...holas Carpita, a professor of plant cell biology, ...s in the journal Plant Physiology on Thursday (N...
(Date:11/19/2009)...LA, CA November 19, 2009 A team led by scientists... a direct link between insulina hormone long assoc... as diabetesand core body temperature. While much ...iscovery in the 1920s, this is the first time the ...ess of temperature regulation. , The paper was p...
(Date:11/19/2009)...E PARK, Md.-John Fisher, associate professor in th...est Inventor Pitch at the 2009 Bioscience Research...ng bioreactor system that grows bone and other typ...logy was one of six innovations presented in an ei...tudents at the Professor Venture Fair, held Novemb...
Breaking Biology News(10 mins):Maize cell wall genes identified, giving boost to biofuel research 2Scripps research scientists find new link between insulin and core body temperature 2Scripps research scientists find new link between insulin and core body temperature 3Scripps research scientists find new link between insulin and core body temperature 4Bioreactor for bone tissue engineering wins professor venture fair 2Bioreactor for bone tissue engineering wins professor venture fair 3With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 1With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 2With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 3With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 4With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 5With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 6Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 57757 1Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 57757 2Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 57757 3Keryx Biopharmaceuticals Inc to Hold Investor Analyst Day Tomorrow 57755 1Keryx Biopharmaceuticals Inc to Hold Investor Analyst Day Tomorrow 57755 2Keryx Biopharmaceuticals Inc to Hold Investor Analyst Day Tomorrow 57755 3
... the most severe form of that group of diseases, a...s caused by a protozoan, Leishmania infantum, tran... this disease, which can rapidly lead to death if ...d areas, the dog population is hit heavily by infe...evelopment of a vaccine for dogs could help brake ...
...cent Live 8 concert broadcasts, some just for the ...rheaded by former Boomtown Rat, Sir Bob Geldof. In...ook out for each other, while others look out for ...tural selection has designed individuals to behave...nd up with more resources and therefore more offsp...
... the loss of a gene called p63 accelerates aging i...n many organisms, including humans. Therefore, the...al role in aging-related processes. , "To study ho...inating it from adult mouse tissues. What struck u...e aging prematurely," says Alea Mills of Cold Spri...
Other Biology News:Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 3Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 4Helping in a selfish world 2Gene loss accelerates aging 2
(Date:11/19/2009)..., SEATTLE, Nov. 19 Omero...udited financial results for the third quarter end...September 30, 2009, Omeros reported a net loss of ... net loss of $7.4 million, or $2.54 per share, for...d September 30, 2009, the Company reported a net l...
(Date:11/19/2009)..., ,, BETHESDA, Md., Nov. 19 /PRNewswire-F..., an innovator in biotechnology for diabetes thera...sulting services to food, supplement, biotechnolog... closed the previously reported $6.3 million regis...of 2,760,870 shares of its common stock and warran...
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 ...or in biotechnology for diabetes therapy, and a pr...ices to food, supplement, biotechnology and pharma... Tuesday,s Annual Meeting of Shareholders. ,, A...d (Nasdaq: SPEX ) elected the following members t...
(Date:11/19/2009)..., MUNSTER, Germany, November 19 /PRNewswire...e filed on November 16th, 2009 Flibanserin in the,...kinesia in Parkinson,s,disease for orphan drug sta...,(EMEA). Levodopa-induced dyskinesia is a complica...on,s and a serious burden to some of those,affecte...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... The Binding Site Limited,("The Binding Site" or ...diagnostics company, today announces the publicati...ing first-line use of Freelite(TM) in the,diagnosi...cells in the bone,marrow, and related plasma cell ...half of the International Myeloma,Working Group ("...
...t of an announcement made recently by Astellas Pha...confirmed that it had received a letter dated Nove...icited proposal by Astellas to acquire CV Therapeu...e diligence, Astellas board approval and other con...he assistance of its financial and legal advisors,...
... responds to the demand in food, beverage and nutr...ading specialty chemical company, Albemarle Corpor...mpany, Zymes LLC, have joined forces to scale-up p...solubilization technology, PTS. The next generati...n-water-soluble vitamins and natural functional in...
Other Biology Technology:International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 3International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 4International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 5International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 6International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 7CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 2Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 3
Goat Anti-synphilin-1 (V-19) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Porcine IFN-gamma ELISpot Kit from R&D Systems
... the basic components required for the development...nant canine Monocyte Chemotactic Protein 1 (MCP-1)...ontains sufficient materials to run ELISAs on appr...e following conditions are met:2 1. For assayi...
Rat Anti-CCR5 Monoclonal Antibody, Unconjugated, Clone HEK / 1 / 85a from Abcam
Biology Products: